Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. In adults with NAFLD, fibrosis can develop and progress to liver cirrhosis and liver failure. However, the underlying molecular mechanisms of fibrosis progression are not fully understood. Using total RNA-Seq, we investigated the molecular mechanisms of NAFLD and fibrosis. We sequenced liver tissue from 143 adults across the full spectrum of fibrosis stage including those with stage 4 fibrosis (cirrhosis). We identified gene expression clusters that strongly correlate with fibrosis stage including four genes that have been found consistently across previously published transcriptomic studies on NASH i.e. COL1A2, EFEMP2, FBLN5 and THBS2. Using cell type deconvolution, we estimated the loss of hepatocytes versus gain of hepatic stellate cells, macrophages and cholangiocytes with advancing fibrosis stage. Hepatocyte-specific functional analysis indicated increase of pro-apoptotic pathways and markers of bipotent hepatocyte/cholangiocyte precursors. Regression modelling was used to derive predictors of fibrosis stage. This study elucidated molecular and cell composition changes associated with increasing fibrosis stage in NAFLD and defined informative gene signatures for the disease.

Details

Title
Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD
Author
Pantano Lorena 1 ; Agyapong, George 2 ; Shen, Yang 3 ; Zhu, Zhuo 1 ; Fernandez-Albert, Francesc 3 ; Rust, Werner 3 ; Knebel Dagmar 3 ; Hill, Jon 4 ; Boustany-Kari, Carine M 4 ; Doerner, Julia F 3 ; Rippmann, Jörg F 3 ; Chung, Raymond T 2 ; Ho Sui Shannan J 1 ; Simon, Eric 3 ; Corey, Kathleen E 2 

 Harvard T.H. Chan School of Public Health, Harvard Chan Bioinformatics Core, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Massachusetts General Hospital, Liver Center, Division of Gastroenterology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
 Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach Riss, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500) 
 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2571040561
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.